The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Rapid Response Innovation Awards, 2012Stimulation of Protein Clearance Mechanisms to Improve Clearance of Toxic Accumulations of Alpha-synuclein
Objective/Rationale:
Alpha-synuclein protein accumulation in the brain causes neurotoxicity in Parkinson’s disease (PD). Neural cells have a protein degradation mechanism called the... -
Novel Approaches to Drug Discovery for PD, 2012Cerium Oxide Nanoparticles in the Treatment of Parkinson’s Disease – Toxicity and Biodistribution Studies
Promising Outcomes of Original Grant:
In our prior years of funding from The Michael J. Fox Foundation, we tested the hypothesis that cerium oxide nanoparticles (CeONP) were a disease-modifying therapy... -
Research Grant, 2012Collaborative Validation of Oxidized DJ-1 Antibodies For PD Biomarker Study
Objective/Rationale:
We have developed antibodies against an oxidized form of DJ-1 using complementary approaches to be able to use them as a biomarker in PD. A common problem in... -
Rapid Response Innovation Awards, 2012CD163+ Macrophages as Tools for Neuroinflammatory Modulation in Parkinson’s Disease
Objective/Rationale:
Evidence in humans and in research models support a role for the immune system in the progression of Parkinson's disease. Our preliminary data suggest infiltration of peripheral... -
Neurotrophic Factors Challenge, 2012Effects of Recombinant CDNF Protein in Alpha-synuclein Model of Parkinson’s Disease in Pre-Clinical Models
Objective/Rationale:Neurotrophic factors have been explored as a novel treatment for Parkinson’s disease. Toxic effect of α-synucleinopathies, one of the hallmarks in PD pathophysiology, occurs in...
-
Target Validation, 2012Small Molecule Ligand for TrkB/TrkC as a Novel Therapeutic for Parkinson's Disease
Objective/Rationale:
Ample evidence suggests that the neurotrophin (NT) receptors, TrkB and TrkC, would be particularly effective therapeutic targets for Parkinson’s disease (PD). Both...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.